# Dose Individualization of Pemetrexed - IMPROVE-I

> **NCT03656549** · PHASE4 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 6 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Mesothelioma

## Interventions

- **DRUG:** Pemetrexed + oral folinic acid rescue

## Key facts

- **NCT ID:** NCT03656549
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-29
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03656549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03656549, "Dose Individualization of Pemetrexed - IMPROVE-I". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03656549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*